Remove Bioavailability Remove Drug Delivery Systems Remove Genetics Remove Marketing
article thumbnail

Breaking the Waves: How Blue Ocean Strategy in Healthcare Can Propel Pharma / Biotech Companies to Success

Roots Analysis

By charting new waters and creating uncontested market spaces, companies can differentiate themselves and unlock unprecedented growth opportunities. In this blog post, I’ll explore how pharma / biotech companies can leverage the blue ocean and red ocean strategy to make waves in the market.

article thumbnail

The Power of Lipids: Enhancing Drug Delivery with Nanoparticles

Roots Analysis

Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.

article thumbnail

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

CNS drugs take more than a year longer to develop and are less than half as likely to receive marketing approval compared to other drugs, according to a 2014 study by the Tufts Center for the Study of Drug Development. Consider targeting your therapies that fail to be orally bioavailable and brain penetrant.

Trials 83